Brief: Tango Therapeutics Reports Third Quarter 2023 Financial Results And Provides Business Highlights
08/11/2023 12:24
Nov 8 (Reuters) - Tango Therapeutics Inc TNGX.O :
* TANGO THERAPEUTICS REPORTS THIRD QUARTER 2023 FINANCIAL
RESULTS
AND PROVIDES BUSINESS HIGHLIGHTS
* STRONG CASH POSITION OF $360 MILLION; CASH RUNWAY INTO
2026
EXPECTED TO FUND ALL CLINICAL PROGRAMS THROUGH PROOF-OF-CONCEPT
* QTRLY NET LOSS $0.23 PER SHARE
* QTRLY TOTAL REVENUE $10.7 MILLION VERSUS $6.9 MILLION
* Q3 EARNINGS PER SHARE VIEW $-0.35, REVENUE VIEW $7.3
MILLION --
LSEG IBES DATA
Source text for Eikon: ID:nGNX5MJMm
Further company coverage: TNGX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tango Therapeutics
See all newsBrief: Tango Therapeutics, Inc. Approved A Strategic Reprioritization Of The Company’S Research And Development Activities
Brief: Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Tango Therapeutics - Files Prospectus To Sell Up To $400 Million In Common Stock
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil,